![Karin Nielsen](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 206 493 $ al 30/09/2026
Karin Sandager Nielsen has been Chief Scientific Officer at Saniona AB since 2022, with employment at the firm starting in 2012.
Dr. Nielsen holds a doctorate from the University of Copenhagen.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
SANIONA AB 0,15 % | 31/12/2025 | 211.119 ( 0,15 % ) | 206 493 $ | 30/09/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| SANA AB | Director Técnico/Científico/I+D | 30/04/2022 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 2 |
|---|---|
University of Copenhagen
 University of Copenhagen Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Saniona AB
 Saniona AB BiotechnologyHealth Technology Engages in the research and development of drugs to treat the central nervous system diseases | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
